What's Happening?
At the 2026 BiOS conference in San Francisco, researchers introduced TissueSense, a biosensing platform designed to enhance the monitoring of living cells and tissues during drug bioprocessing. This system offers continuous, real-time insights into cellular
behavior without disrupting the biological environment. Traditional methods often rely on intermittent sampling, which provides limited visibility into dynamic processes. TissueSense addresses this by enabling continuous observation, capturing changes as they occur. The platform uses resonator-based photonic sensing and phase contrast microscopy to detect biochemical activity and structural changes in cells simultaneously. This dual approach offers a comprehensive view of cellular responses to process conditions, such as nutrient shifts or environmental stress, which are crucial for production outcomes. TissueSense operates without fluorescent markers, allowing for extended observation in conditions closer to natural states. Data from the platform are analyzed using machine learning to quantify up to 18 biomarkers, linking molecular outputs to tissue structure and function.
Why It's Important?
The introduction of TissueSense marks a significant advancement in biopharmaceutical manufacturing, where maintaining consistent cell health and productivity is critical. By providing continuous, non-destructive monitoring, the platform allows for dynamic control of biological production, potentially improving yield, quality, and reproducibility. This technology is particularly relevant in drug manufacturing, where small variations in cellular activity can have significant impacts. The ability to monitor and adjust processes in real-time could lead to more efficient and cost-effective production methods. Additionally, the platform's label-free operation removes constraints associated with traditional biosensing methods, supporting long-term monitoring and reducing the risk of altering cell behavior.
What's Next?
The development of TissueSense and similar technologies suggests a shift towards more integrated bioprocess monitoring across various systems, including mammalian, yeast, and bacterial. Continuous, high-resolution monitoring is becoming increasingly feasible, allowing researchers and manufacturers to move beyond static measurements. This could lead to further innovations in bioprocessing, with potential applications in strain optimization and industrial bioproduction. As these technologies evolve, they may also influence regulatory standards and best practices in the biopharmaceutical industry.
